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ABSTRACT
Background: In 2007, ESAC (http://www.esac.ua.ac.be)
published a set of 12 valid drug-specific quality
indicators for outpatient antibiotic use in Europe.
In this study, the authors aimed to develop
evidence-based disease-specific quality indicators for
outpatient antibiotic prescribing in Europe.
Methods: Two meetings were convened to produce
a list of disease-specific quality indicators for
outpatient antibiotic prescribing which conform to
internationally agreed recommendations, building on
a similar development of drug-specific quality
indicators, and in collaboration with CHAMP and
HAPPY AUDIT. 62 experts were asked to complete two
scoring rounds of the proposed indicators on seven
dimensions: their relevance to (1) reducing
antimicrobial resistance, (2) patient health benefit, (3)
cost-effectiveness, (4) policy makers, (5) individual
prescribers, (6) their evidence base and (7) their range
of acceptable use, using a scale ranging from 1
(¼completely disagree) to 9 (¼completely agree).
Scores were judged according to the UCLA-RAND
appropriateness method.
Results: For the six main indications for antibiotic
prescribing (acute otitis media, acute upper-
respiratory infection, acute/chronic sinusitis, acute
tonsillitis, acute bronchitis/bronchiolitis, cystitis/other
urinary infection) and for pneumonia, three quality
indicators were proposed, the percentage prescribed
(a) antibiotics; (b) recommended antibiotics; (c)
quinolones. This set was scored by 40 experts from
25 countries. After one scoring round, all indicators
were already rated as relevant on all dimensions,
except one.
Conclusion: All proposed disease-specific quality
indicators for outpatient antibiotic prescribing have
face validity and are potentially applicable. They could
be used to better describe antibiotic use and assess
the quality of antibiotic prescribing patterns in
ambulatory care.
INTRODUCTION
In 2007, the European Surveillance of
Antimicrobial Consumption project (ESAC,
http://www.esac.ua.ac.be) published a set of
12 valid quality indicators for outpatient
antibiotic use in Europe.1 Antibiotic use is
increasingly recognised as the main driver for
antimicrobial resistance,2e4 and, if we want to
improve antibiotic use, we have to be able to
measure its quality. Meanwhile, in the USA,
total antibiotic consumption is included as a
quality indicator by the National Committee
for Quality Assurance (NACQ; http://www.
ncqa.org/Portals/0/HEDISQM/HEDIS2009/
2009_Measures.pdf), and in Scotland, the
Scottish government and the Scottish Anti-
microbial Prescribing Group have agreed
that seasonal variation of quinolone use
should be #5% (http://www.sehd.scot.nhs.
uk/mels/CEL2009_11.pdf). These quality
indicators, however, might not be as relevant
for individual prescribers as they are for
policy makers, since clinicians need disease-
specific indicators rather than drug-specific
indicators.1
The largest volumes of antibiotic prescrip-
tions for systemic use are prescribed in
primary care,2 with respiratory-tract infec-
tions (RTI) and urinary-tract infections being
the most common indications.5 The effect of
antibiotic prescribing in primary care for
these conditions on antimicrobial resistance
can be observed at individual patient-3 4 and
practice levels.6 Reducing antibiotic dispensing
at general-practice level is associated with
reduced local antibiotic resistance.6
Since resistance is not limited by the borders
of a practice, county or country, we aimed
to develop a set of relevant evidence-based
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disease-specific quality indicators for outpatient antibiotic
prescribing that is measurable on each of these levels in
Europe, using a similar methodology to that we used
before to develop the drug-specific quality indicators.
METHODS
Developing a set of quality indicators
Quality indicators are defined as explicitly defined
measurable items of antibiotic use giving a possible
indication of the level of quality,7 8 focusing on different
aspects of quality (effectiveness, safety, appropriateness
and costs9; compliance and persistence) and relevant for
clinical practice.10 A prescribing quality indicator is
a measurable element of prescribing performance,
for which there is evidence or consensus that it can be
used to assess quality and, hence, be used in changing
the quality of care provided.11 See box 1, for more
information about quality indicators.
To produce a draft list of evidence-based disease-
specific antibiotic prescribing quality indicators in
Europe, two meetings were convened in Antwerp by the
ESAC Ambulatory Care Subproject Group, funded by
the European Centre for Disease prevention and
Control (ECDC) (figure 1). During the first meeting in
June 2008, the ESAC drug-specific quality indicators
were presented, as well as results from two European
projects, Health Alliance for Prudent Prescribing, Yield
and Use of Antimicrobial Drugs in the Treatment of
Respiratory Tract Infections (HAPPY AUDIT; http://
www.happyaudit.org)15 and Changing behaviour of
Healthcare professionals And the general public
towards a More Prudent use of antimicrobial agents
(CHAMP; http://www.champ-antibiotics.org),16 with
closely related objectives. HAPPY-AUDIT shared its
useful experience in developing quality indicators for
diagnosis and treatment of RTI in general practice using
Box 1 Prescribing quality indicators: definition and
requirements
- A prescribing quality indicator (PQI) is a measurable
element of prescribing performance for which there is
evidence or consensus that it can be used to assess
quality and, hence, be used in changing the quality of
care provided.11 Usually, a PQI is defined as
a percentage of patients who received the recommended
drug treatment, with the numerator comprising the
number actually receiving the treatment and denominator
comprising the number of all patients for whom the
treatment is appropriate. PQIs have explicitly defined
criteria regarding what constitutes good quality of care,
and the values of the PQI can be compared over time
and across different providers. Usually, PQIs are
developed based on scientific evidence and/or accep-
tance by professionals in the field.7 Therefore, they can
be used to measure the compliance with drug recom-
mendations as given in clinical guidelines. When
implementing PQIs in daily practice, unintended conse-
quences of publishing performance data as described by
Smith et al should be taken into account.12 That is why
the requirements regarding validity and reliability of PQIs
depend on the aim of their use. For internal purposes,
PQIs need to be relevant for healthcare providers: they
have to be specific and sufficiently detailed to show
potential problems and capture pertinent changes in
prescribing. However, for a fair comparison between
healthcare providers for external use, for example by
third-party payers, there are additional requirements,
such as adjustment for patient case-mixes and having an
adequate number of patients per provider.13
- Measurability of PQIs provides a great opportunity for
researchdfor example, for comparison of indicator
scores to assess their concurrent validity or by linking
the scores of prescribing indicators to different patients’
outcomes for predictive validity assessment.14
First preparatory meeting Discussion objectives
ESAC AC NR, CHAMP, HAPPY AUDIT Presentation CHAMP & HAPPY AUDIT project
Second preparatory meeting Discussion HAPPY AUDIT proposal
ESAC AC NR, DURQUIM DURQUIM presentation
Presentation guideline based QI proposal
List of proposed indicators
ESAC, GRIN, GRACE, APRES Scoring and comments
WHO, BAPCOC, other experts
ESAC, GRIN, GRACE, APRES Review, revision and approval
WHO, BAPCOC, other experts
Final manuscript
Figure 1 Development of outpatient disease-specific
antibiotic prescribing quality indicators. APRES, The
Appropriateness of prescribing antibiotics in primary
healthcare in Europe with respect to antibiotic resistance
(http://www.nivel.eu/apres); BAPCOC, Belgian Antibiotic
Policy Coordination Committee (http://www.bapcoc.be/);
CHAMP, Changing behaviour of Healthcare professionals And
the general public towards a More Prudent use of antimicrobial
agents (http://www.champ-antibiotics.org); DURQUIM, Drug
Utilisation Research Quality Indicators Meeting11; ESAC AC
NR, European Surveillance of Antimicrobial Consumption
Ambulatory Care subproject National Representative (http://
www.esac.ua.ac.be/); GRACE, Genomics to combat
Resistance against Antibiotics in Community-acquired LRTI in
Europe (http://www.grace-lrti.org/); GRIN, General Practice
Respiratory Infections Network; HAPPY AUDIT, Health
Alliance for Prudent Prescribing; Yield And Use of antimicrobial
Drugs In the Treatment of Respiratory Tract Infections (http://
www.happyaudit.org/); WHO, World Health Organization
(http://www.who.int/).
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a modified Delphi methodology, and CHAMP shared
information on its collection and comparison of national
guidelines for RTI (including acute lower-RTIs, acute
sore throat, acute otitis media and acute sinusitis).
A second ESAC meeting was held 1 year later to
present and discuss the DURQUIM framework for
quality indicators,11 the HAPPY AUDIT quality indica-
tors for diagnosis and treatment of RTI,15 17 as well as
a draft list of ESAC disease-specific quality indicators
using guidelines (collected in CHAMP) as the evidence
base. This draft list consisted of 12 indicators, two for
each of the six indications for which most antibiotics are
being prescribed. These indications were selected based
on IMS Health data linking primary care antibiotic
prescribing data with indications labelled with codes
from the revised second edition of International Classi-
fication of Primary Care (ICPC-2-R)18 for France,
Germany, Italy, Spain and the UK. After the second
meeting, NA and SC developed a proposed list of ESAC
disease-specific quality indicators taking into account the
discussions and using a similar outline as for the ESAC
drug-specific quality indicators that is each indicator
description contains an indicator number, a title
(Label), definition, public health objective, calculation
formula, range of acceptable use, recommended actions,
limitations and references (to (inter)national guidelines)
(table S1).
During both meetings, the presence of clinicians and
scientists with expertise in general practice, microbi-
ology, infectious diseases, pharmaco-epidemiology,
pharmacy and/or drug utilisation allowed the develop-
ment of quality indicators from the perspective of
professionals to be discussed, and a proposed set of
disease specific antibiotic prescribing quality indicators
as well as a roadmap describing the next steps with these
indicators to be produced. More details on the method
of indicator development have been described elsewhere
(table S1).
Assessing a set of quality indicators
To assess the relevance of the proposed disease-specific
quality indicators, two consecutive cycles of scoring were
performed. For this purpose, we aimed to select experts
with known expertise primarily in general practice and
secondarily in infectious diseases, microbiology, phar-
maco-epidemiology, pharmacy, quality indicators devel-
opment and/or drug utilisation. Therefore, the ESAC
lead National Representatives were asked to identify an
expert meeting these criteria. In addition, experts were
selected among the participants of several EU projects
relevant to this topicdfor example, GRACE, APRES, etc
(figure 1). Sixty-two experts from 33 countries were sent
an email containing the proposed set of quality indicators
and a scoring sheet. They were invited to score the
proposed set of disease-specific antibiotic prescribing
quality indicators on seven dimensions, that is their rele-
vance to (1) reducing antimicrobial resistance, (2) patient
health benefit, (3) cost-effectiveness, (4) policy makers,
(5) individual prescribers, (6) their evidence base and
(7) their range of acceptable use, using a scale ranging
from 1 (¼completely disagree), over 5 (¼uncertain) to
9 (¼completely agree). If participants did not agree with
the range of acceptable use (score: 1e5), they were asked
to suggest a new acceptable lower and upper limit. Experts
were welcome to make any suggestion to improve the
description of the proposed indicators, ideally providing
supporting evidence. These were to be taken into account
in the second round of scoring.
In the second round of scoring, experts were given the
opportunity to reconsider their score. They were sent an
email now containing the same proposed set of quality
indicators and a scoring sheet with their original score as
well as the median score of all respondents per indicator
and per dimension.
The scores were processed according to the UCLA-
RAND appropriateness method.19 20 Proposed indica-
tors were judged relevant if the median score was not
within the 1e6 interval, and if there was consensus, that
is if the number of scores within the 1e3 interval was less
than one-third of the panel.
Defining a final set of quality indicators
To define the final set, only relevant indicators were
selected.
RESULTS
As a result of two ESAC Ambulatory Care Subproject
Group meetings, it was concluded that a proposed list of
quality indicators will be developed for the six most
frequent indications for antibiotic prescribing (in
descending order: acute bronchitis/bronchiolitis, acute
upper RTI, cystitis/other urinary infection, acute tonsil-
litis, acute/chronic sinusitis, and acute otitis media; data
not shown) and for pneumonia (labelled with ICPC-2-R
codes R78, R74, U71, R76, R75, H71 and R81, respec-
tively). In addition, it was decided not to adopt the
HAPPY AUDIT quality indicators, mainly because it is
difficult to assess their evidence base, based on their
description, and to produce indicator values using data
routinely collected in electronic medical health records
in primary care. For each of these seven indications,
three indicators were proposed:
a. the percentage of patients with age and/or gender
limitation prescribed an antibiotic;
b. the percentage of patients with age and/or gender
limitation prescribed an antibiotic, and receiving the
guideline recommended antibiotic;
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c. the percentage of patients with age and/or gender
limitation prescribed an antibiotic, and receiving
quinolones (tables 1, and S1).
The indication ‘pneumonia’ as well as the third indi-
cator (c) resulted from the discussion during the second
ESAC meeting.
All 21 indicators were described in a way that allowed
them to be read and scored separately. Therefore, parts
of their description were very similar.
We received scores from 40 participants (12 women; 25
countries). Eight experts declined (six no time, two no
longer active in the research field), three experts
forwarded their invitation to another expert within their
network, and 14 did not respond. After the first round of
scoring, all indicators were rated as relevant (ie, score
not within the 1e6 interval) quality indicators on all
seven dimensions except 3a, that is the percentage of
female patients older than 18 years with cystitis/other
urinary infection (ICPC-2-R: U71) prescribed antibacte-
rials for systemic use (ATC: J01), which was scored 6 for
cost-effectiveness.
Similar scores were received after the second scoring
round (table 2.)
The median score per dimension across all 21 indica-
tors was about 8, with only minor differences in median
score per dimension between individual indicators.
Table 1 List of proposed disease specific antibiotic prescribing quality indicators in Europe
No Title Label Acceptable range (%)
1a. Percentage of patients aged between 18 and 75 years with
acute bronchitis/bronchiolitis (ICPC-2-R: R78) prescribed
antibacterials for systemic use (ATC: J01)
(R78_J01_%) 0e30
1b. ¼1a receiving the recommended antibacterials (ATC: J01CA
or J01AA)
(R78_RECOM_%) 80e100
1c. ¼1a receiving quinolones (ATC: J01M) (R78_J01M_%) 0e5
2a. Percentage of patients older than 1 year with acute upper
respiratory infection (ICPC-2-R: R74) prescribed antibacterials
for systemic use (ATC: J01)
(R74_J01_%) 0e20
2b. ¼2a receiving the recommended antibacterials (ATC: J01CE) (R74_RECOM_%) 80e100
2c. ¼2a receiving quinolones (ATC: J01M) (R74_J01M_%) 0e5
3a. Percentage of female patients older than 18 years with cystitis/
other urinary infection (ICPC-2-R: U71) prescribed
antibacterials for systemic use (ATC: J01)
(U71_J01_%) 80e100
3b. ¼3a. receiving the recommended antibacterials (ATC: J01XE
or J01EA or J01XX)
(U71_RECOM_%) 80e100
3c. ¼3a receiving quinolones (ATC: J01M) (U71_J01M_%) 0e5
4a. Percentage of patients older than 1 year with acute tonsillitis
(ICPC-2-R: R76) prescribed antibacterials for systemic use
(ATC: J01)
(R76_J01_%) 0e20
4b. ¼4a receiving the recommended antibacterials (ATC: J01CE) (R76_RECOM_%) 80e100
4c. ¼4a receiving quinolones (ATC: J01M) (R76_J01M_%) 0e5
5a. Percentage of patients older than 18 years with acute/chronic
sinusitis (ICPC-2-R: R75) prescribed antibacterials for
systemic use (ATC: J01)
(R75_J01_%) 0e20
5b. ¼5a receiving the recommended antibacterials (ATC: J01CA
or J01CE)
(R75_RECOM_%) 80e100
5c. ¼5a receiving quinolones (ATC: J01M) (R75_J01M_%) 0e5
6a. Percentage of patients older than 2 years with acute otitis
media/myringitis (ICPC-2-R: H71) prescribed antibacterials
for systemic use (ATC: J01)
(H71_J01_%) 0e20
6b. ¼6a receiving the recommended antibacterials (ATC: J01CA
or J01CE)
(H71_RECOM_%) 80e100
6c. ¼6a receiving quinolones (ATC: J01M) (H71_J01M_%) 0e5
7a. Percentage of patients aged between 18 and 65 years with
pneumonia (ICPC-2-R: R81) prescribed antibacterials for
systemic use (ATC: J01)
(R81_J01_%) 90e100
7b. ¼7a receiving the recommended antibacterials (ATC: J01CA
or J01AA)
(R81_RECOM_%) 80e100
7c. ¼7a receiving quinolones (ATC: J01M) (R81_J01M_%) 0e5
*Full name of the chemical subgroup according to the Anatomical Therapeutic Chemical (ATC) classification; J01AA, tetracyclines; J01CA,
penicillins with extended spectrum; J01CE, beta-lactamase sensitive penicillins; J01EA, trimethoprim and derivatives; J01M, quinolone
antibacterials; J01XE, nitrofuran derivatives; J01XX, other antibacterials.
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Indicators 1e6 had a high median score for relevance to
reducing antimicrobial resistance and a low median
score for relevance to patient health benefit, while it was
the other way around for indicator 7. For relevance to
individual prescribers, indicator 6c had the highest
median score, followed by 2a, 2c, 3c and 6b, while 3a had
the lowest median score.
DISCUSSION
Taking into account the scores from a relevant group of
expertsdprofessionals rather than policy makersdfrom
a set of 21 (733) proposed guideline based disease-
specific quality indicators for outpatient antibiotic use in
Europe, all seem to be relevant, that is, they have face
validity and are potentially applicable. Only one
proposed indicator, the percentage of female patients
older than 18 years with cystitis/other urinary infection
(ICPC-2-R: U71) prescribed antibacterials for systemic
use (ATC: J01), was not scored as relevant for one out of
seven dimensions, that is for cost-effectiveness. The fact
that not all countries, for example the UK, recommend
antibacterials in the treatment of urinary-tract infection
could be a possible explanation.21
These results are remarkable, since they were already
achieved after the first of two rounds of scoring. And what
is more, the expert panel consisted of experts from 24
different countries all over Europe and Israel (figure 2).
Because all quality indicators are well defined, the risk of
misinterpretation is limited. In addition, for all indica-
tors, an evidence base was provided, based on current
national guidelines, and this was scored as relevant.
Some limitations have to be taken into account
specifically for these quality indicators. When inter-
preting the indicators expressing the percentage of
patients prescribed an antibiotic (ie, table 1, 1ae7a),
where lower scores represent better quality of care
except for cystitis and pneumonia, different thresholds
for consulting a GP because of differences in healthcare
organisation in primary care settings22 can influence the
acceptable range. Delayed prescribing is another reason
for potential bias in the interpretation of values for these
quality indicators. The percentage of patients prescribed
the recommended antibiotics (ie, table 1, 1be7b), where
higher scores represent better quality of care, can be
biased by country-specific guidelines recommending
other antibiotic classes as first-line therapydfor
example, small spectrum penicillins for acute otitis
media (H71) in Scandinavian countries.23 24 The
percentage of patients prescribed quinolones (ie, table 1,
1ce7c), where lower scores represent better quality of
care, which has also been suggested as a quality indicator
by Altiner et al,25 can be biased by specific resistance
patterns.
Differentiating between acute pharyngitis (¼ICPC-2-R:
R74, acute upper RTI) and acute tonsillitis (¼ICPC-2-R:
R76, acute tonsillitis) can still be challenging or even
impossible if coinciding. Since essentially the quality
indicators for these diagnoses, 2aec and 4aec, respec-
tively, do not differ, it could be tempting to merge them
into one indicator, for example, for 2a and 4a: the
percentage of patients older than 1 year with acute
upper RTI (ICPC-2-R: R74) or with acute tonsillitis
(ICPC-2-R: R76) prescribed antibacterials for systemic
use (ATC: J01). At this stage, however, we prefer to
consider them as separate indicators, since for acute
upper RTI (including pharyngitis) there is less evidence
to support antibiotic prescribing than for acute tonsil-
litis. There are certain subgroups of patients with acute
tonsillitis, for example, those with a history of rheumatic
fever, who might benefit from antibiotics.
Our quality indicators are based on national guide-
lines. Looking for consensus, we choose to take
a conservative position for example for age limits. Since
national guidelines are composed of available best
evidence and expert opinions which can evolve over
time, a regular review of these indicators will be
preferable.
Other general limitations regarding consensus
methods, for example possible language barriers that
apply to our work as well, have been described in detail
elsewhere.17
Figure 2 Map of Europe (+Israel): the number in each
country represents the number of experts participating in the
expert panel.
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Indicator 7 is the only indicator for which antibiotic
prescribing is generally advised. Therefore, relevance to
patient health benefit is probably scored higher than
relevance to reducing antimicrobial resistance, while for
the other indicators, it is the other way around.
Compared with the ESAC drug-specific indicators, which
were all scored as relevant to reducing antimicrobial
resistance and to policymakers, but not always to patient
health benefit and cost-effectiveness, the disease-specific
quality indicators scored relevant on all these and three
extra dimensions, except 3a (cf supra). The disease-
specific indicators therefore indeed seem to be more
useful to individual prescribers. In addition, for all
indicators, relevance to individual prescribers was scored
higher than or as high as relevance to policymakers.
The percentage of patients older than 2 years with
acute otitis media/myringitis (ICPC-2-R: H71) prescribed
antibacterials for systemic use (ATC: J01), receiving
quinolones (indicator 6c), obtained the maximum
score in the dimension relevance to individual
prescribers. This is probably explained by the
high prevalence of otitis media in children for which
quinolones are not advised.
We believe the most relevant indicator probably is that
which identifies actual problems with the quality of
outpatient antibiotic prescribing rather than that which is
most relevant on one specific or all dimensions. The
indications for which the highest amount of inappro-
priate antibiotics are prescribed can be different at
practice-, county- or country level. In addition, and
similar to our advice regarding the use of the drug-
specific quality indicators,1 we do not recommend
assessing the quality of outpatient antibiotic prescribing
by looking at a single quality indicator. After all, accept-
able antibiotic prescribing proportions for one indication
might coincide with unacceptable antibiotic prescribing
proportions for other indications or with unacceptable
proportions of antibiotics that are not recommended,
and vice versa. Hence, we talk about a set of indicators.
Unlike the ESAC drug-specific quality indicators for
which values can be derived from ESAC data, for these
disease-specific quality indicators data linking antibiotic
prescriptions with patients’ age/gender and diagnosis
are not readily available.
A Dutch study in which clinical information from
individual patients was linked to antibiotic use, and
guidelines were used as a quality benchmark,26 assessed
the quality of antibiotic prescribing related to indication.
This was even done on a national scale in The
Netherlands,27 Denmark28 and Finland,29 but in many
European countries this is not feasible on a routine base
at present.
Our quality indicators are linked to disease using the
revised second edition of International Classification of
Primary Care (ICPC-2-R) codes. While we are aware that
in daily general practice, the link between a diagnostic
label or code and the actual disease might not always be
reliable, we believe that linking to an international
classification is the most pragmatic solution. Since
publication by WONCA in 1987,18 ICPC has received
increasing world recognition as an appropriate and
comprehensive classification for general/family practice
and primary care, and has been used extensively in some
parts of the world, notably in Europe and Australia. The
WHO has accepted ICPC as a WHO-related classification
to be used for health-information registration in primary
care. Additionally, ICPC-2 has been mapped to the 10th
revision of the WHO International Classification of
Diseases (ICD-10).30
In the ESAC Ambulatory Care Subproject, we aim to
gather routinely collected general practitioners’ antibi-
otic prescribing data linked to indication expressed in
ICPC-2-R or ICD-10 to substantially broaden our inter-
pretation of the striking variation in antibiotic use
between European countries, and to produce values
for the final set of 21 evidence-based disease-specific
quality indicators. However, the collection of these data
has been challenging. Other projects have shown that
such routinely collected data exist in most European
countriesdfor example, Electronic Health Indicator
Data.31 These data are, however, not easily accessible or
have not been processed. The publication of these
quality indicators will hopefully result in increased
accessibility of these routinely collected data sources.
Once this hurdle is overcome, our quality indicators
will be very easy to implement, even at the level of the
individual primary care prescriber using electronic
medical records with ICPC coding for diagnosis, and
ATC coding for antibiotic prescriptions. This is in
contrast to other primary-care quality indicators that
require information like CRP values or Anthonisen
criteria as in the HAPPY AUDIT quality indicators.17
Comparisons between peers has been considered an
important stimulus to quality improvement, for example,
to antibiotic consumption as well.32 If our proposal is
considered acceptable by general practitioners, our final
set of quality indicators could allow GPs, practices,
networks or even individual countries to assess their
position in relation to others. This could trigger actions
to improve antimicrobial prescribing. It could also allow
the identification of temporal trends and regional
differences, and therefore trigger evaluation and action.
Finally, this set of indicators will be available to inform
the process of development, implementation and eval-
uation of national and regional guidelines, and thus be
useful for policy makers as well.
Although the acceptable range was scored relevant,
the use of this range as a real benchmark should be
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considered carefully. In our opinion, one benchmark
value on a European level cannot be given, but rather
a range of acceptable indicator values should be
defined.33 Several contextual factors, such as local
guidelines, and different thresholds for consulting a GP
because of differences in healthcare organisation in
primary care settings22 have to be taken into account.
Hence, we believe these disease-specific quality indica-
tors for outpatient antibiotic prescribing can be the same
in all countries, but the interpretation could vary from
country to country.
Thus, some of the variations revealed by routine data
may reflect real and important variations in actual
healthcare quality, that is inappropriate antibiotic use,
that merit further investigation and action, but some
apparent variation may also arise because of other
misleading factors such as unadjusted case-mix
differences.13
Using information from recorded diagnoses can
introduce bias owing to incomplete registration when
some patients with a condition do not have a corre-
sponding diagnostic code registered in the data or owing
to incorrectly registered diagnostic codes.34 When there
is information bias in the documentation of diagnoses in
relation to the treatment status, the use of diagnostic
codes alone can mislead both policy makers and
healthcare providers about the performance scores of
quality indicators. In such cases, a combination of diag-
nostic codes and clinical information is recommended
for prescribing quality assessment.35 If register-based
proxies for diagnoses, disease severity or risk factors are
employed, validation is essential.36 Assessment of the
concurrent validity of these indicators by comparing with
a ‘gold standard’ quality assessment at the patient level
using all available clinical information will be an
important next step. This assessment will also help to
decide whether or not indicators on acute upper RTI
and acute tonsillitis can be merged.
In conclusion, our work could be considered as a solid,
next step in the development of a set of valid and
feasible evidence-based disease-specific quality indicators
for antibiotic prescribing in Europe. Consequently, the
challenge is to further validate these indicators for
individual prescribers. However, until then, even without
correction for resistance patterns and other contextual
factors, the reported final set of ESAC disease-specific
quality indicators can be used to describe antibiotic use
in ambulatory care in order to assess the quality of
antibiotic prescribing.
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